Study of the Effects of MDMA/Ecstasy on Water Regulation, Sleep, and Cognition.

Completed · Not applicable · Has a placebo group

Conditions studied: MDMA Discontinuation Syndrome

In brief

The purpose of this study is to measure the effects of MDMA on sleep, mood, thinking, and how your body retains water. The researchers are interested in the effects that occur a few hours after taking MDMA as well as effects occurring over the next two days. We will study these effects in a standardized, controlled setting at the Clinical and Translational Science Institute (CTSI) Clinical Research Center (CRC) located at San Francisco General Hospital. The primary hypotheses are: 1. MDMA will induce sleep disruption, as indicated by comprehensive polysomnography, wrist actigraphy, and self-report sleep measures 2. MDMA will alter sodium and water homeostasis by either increasing or blunting the suppression of arginine vasopressin levels and decreasing free water excretion. Effects will be exacerbated by water loading. Secondary hypotheses: 1. Acutely, MDMA will increase both positive and negative arousal, and to increase sociability but not autonomy. 2. Acutely, MDMA will increase risk-taking and willingness to donate money to others in an economic decision making task. 3. MDMA will decrease the stressful effects of talking about a negatively-valenced autobiographical but will increase recall for details for these episodes. 4. MDMA will increase oxidative stress markers and possible ameliorating factors (e.g., ADMA). 5. The short form of the serotonin transported promoter region will be associated with greater acute and discontinuation effects of MDMA.

Key facts

Study ID

NCT01053403

Run by

California Pacific Medical Center Research Institute

People needed

12

Starts

2010-04-01

Expected to finish

2011-02-01

Last updated by the study team

2013-05-31

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy men or women aged 18 to 50 years.
• If female: abstains from heterosexual sex, not of childbearing potential, or reports using an approved contraceptive.
• Experienced with MDMA
• Fluent in English.
• Willing and able to give written consent.
• Healthy without medical contraindications to MDMA administration determined by the following: medical history, physical examination, 12-lead EKG, hematology, blood chemistry, and urinalysis.
• Blood liver transaminase elevations up to 3 times the upper limit of normal.
• If female: negative pregnancy test at screening and at the beginning of each hospital admission.
• Negative urine drug test at screening and prior to each potential MDMA administration.

You may not qualify if…

• Current enrollment in a MDMA, alcohol, or other drug treatment program or current legal problems relating to MDMA, alcohol, or other drug use, including awaiting trial or supervision by a parole or probation officer.
• Participants with a past-history of using only low doses of MDMA
• Currently trying to quit MDMA use.
• Current dependence on any other psychoactive drug (including nicotine).
• Significant physical or psychiatric illness that might impair the ability to safely complete the study or that might be complicated by the study drugs, including prior seizures (after age 8) or other active neurological disease or clinically significant abnormalities on physical examination or screening laboratory values.
• Likelihood of needing medications to treat an illness during the study period.
• Body Mass Index > 30 or < 18.
• HIV seropositive by self-report.
• If female: pregnancy or lactation.
• History of serious adverse event or hypersensitivity to MDMA.
• Currently taking any medication other than over-the-counter non-steroidal anti-inflammatories, topical medications, inhaled asthma therapy, and over-the-counter non-sedating antihistamines.
• Male neck size ≥ 17 inches, female neck size ≥ 16 inches
• Modified Mallampati class ≥ 3.
• Recent travel within 3 days to or from a different time zone, other than Mountain Standard Time.
• Any other medical or psychosocial condition that would preclude useful, safe, or consistent participation.

Where it is running

• CPMC Addiction & Pharmacology Research Laboratory (APRL) — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.